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Abstract 
 Imidazolium salt compounds have shown promise in vitro against non-small cell lung cancer 
(NSCLC) lines, but the exact mechanism of activity these compounds is still unknown.   Due to their 
planar aromatic structure, we hypothesized that our bis-cation imidazolium salt series could act through 
DNA intercalation similar to known intercalators ethidium bromide, acridine orange, and echinomycin.  
Here, we tested bis-cation imidazolium salts with linkers of 2, 4, 10, and 12 carbons for DNA 
intercalation via viscosity and fluorescent intercalator displacement (FID) assays.  Despite some solubility 
issues that may have decreased results, we found that our butyl and dodecyl linked compounds had 
activity exceeded that of known intercalator, acridine orange.  Results from the FID assay were less 
profound and none of the compounds were able to significantly displace ethidium bromide as an 
intercalator in a DNA solution.  These findings indicate that bis-cation imidazolium salts likely do not 
have mechanistic activity against DNA, and future studies should evaluate other intracellular targets to 
determine the mechanism.  
 
Introduction 
In 2016, it is projected that 224,390 new cases of lung cancer will be diagnosed, 83% of which 
will be characterized as NSCLC.1 Currently, the pharmaceutical drug cisplatin is utilized for a variety of 
cancer cell lines due to its activity, but its effectiveness is not without a cost.  Use of cisplatin can lead to 
toxicity and associated adverse effects in patients.2 The focus of the Youngs group is to synthesize 
imidazole compounds that can match the activity of cisplatin while reducing the adverse effects.  
Synthesis of our imidazolium salts have centered around the addition of aromatic planar groups, such as 
naphthalene, to the 1,3 positions on the imidazole ring.3  The planar structure of these compounds led to 
the hypothesis that their activity could mimic the effects of known DNA intercalators such as ethidium 
bromide and acridine orange.4  Activity of these imidazole compounds against NSCLC lines have shown 
promise in vitro, however, knowledge of their specific mechanism of action is limited.  
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 The purpose of this project is to begin studies to investigate the mechanistic activity of our bis-
cation series of imidazolium salts in cancer lines through viscosity and fluorescent intercalator 
displacement (FID) assays. Due to the planar aromatic nature of these compounds, we propose that DNA 
is a viable intracellular target to begin investigating.   Motivation for the synthesis of double intercalation 
compounds such as our bis-cation series has stemmed from research on echinomycin, a known double 
intercalator.5 Our bis-imidazolium cation series is composed of compounds containing 1-12 carbons 
existing between imidazolium rings bound with naphthalene groups (Figure 1).  Based off of our 
knowledge of echinomycin, we hypothesize that our bis-cation series could possibly double intercalate 
DNA and the length of the linker between the imidazole groups will greatly effect when and how this 
intercalation will occur.  
 
 
Figure 1. The bis-cationic imidazolium series that will be tested with 1-12 carbons existing as the n group 
and hydrogen as the R groups. 
 
When intercalation occurs, base pairs surrounding the intercalation site will bend due to the strain 
placed on the DNA.  To relieve this strain the DNA backbone will partially unwind, fractionally 
increasing the length of the DNA which will be detectable during a test of viscosity.6  Our FID studies 
will rely on a titration of our compounds into a DNA solution intercalated with ethidium bromide.  The 
pi-pi interaction between the planar, aromatic rings of ethidium bromide and the base pairs of DNA create 
a significant increase in fluorescence.  Our hope is that our compounds will displace the ethidium 
bromide and intercalate the DNA represented by a detectable decrease in fluorescent intensity.7 With 
combined results from viscosity and FID studies, we will be able to better understand how our 
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compounds interact with and intercalate DNA and how linker length may provide insight into how bis-
cation species can be modified in the future.   
Materials and Methods 
Reagents 
 Bis-cation imidazolium salts with linkers of 2, 4, 10 and 12 were chosen for analysis.  The 
compounds were synthesized by fellow undergraduate student Stephen Crabtree. Due to the compounds’ 
varying degrees of solubility in water, dimethyl sulfoxide (DMSO, Fisher Scientific) was used at 10% 
volume for both viscosity and FID assays.   
 Calf thymus DNA (CT-DNA, Invitrogen) solutions that were used for both the viscosity and FID 
assay were created combining CT-DNA and tris-NaCl buffer (Buffer was created using Invitrogen 
UltraPureTM Distilled Water with Fisher Scientific tris at 5 mM and NaCl at 50 mM).  A DNA 
concentration within the range of 225-250 μM for the viscosity assay and 115-135 μM for the FID assay 
were desired.  For the viscosity DNA stock, 560 μL of CT-DNA with an initial concentration of 10 
mg/mL was added to 70 mL of tris-NaCl buffer.  For the FID stock solution, these values were only 30 
mL of buffer and 123 μL of CT-DNA. These solutions were mixed thoroughly with swirling and a sample 
from each was tested for concentration using an ultraviolet-visible spectrophotometer (Cary 100 Bio UV-
Visible Spectrophotometer).  The absorbance values collected from the peaks of the readings were 
divided by the extinction coefficient of the CT-DNA, 6600 M-1 cm-1 to obtain the concentration of DNA 
in solution.6 If the target concentration for the assay was not obtained after the initial additions 
adjustments to the volume of CT-DNA or buffer were made accordingly until the solution was brought 
into the appropriate range as verified by the UV-Vis.  
Weighing compounds for solutions  
Solutions for each of the compounds were created so that the concentration of compound was 
increased 10 μM per 8 μL addition for viscosity and 3.33 μM per 2 μL addition for FID. This meant that 
our 1 mL compound solutions would need to be 10 mM solutions for viscosity and 5 mM for FID.  Using 
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the varying molecular masses of the compounds being tested with the known total volumes and 
concentration values, the masses needed for each of the compounds were calculated as seen in Table 1.  
Viscosity Assay 
 The methods for the viscosity assay were adapted from Fu et al.7 A 10 mL viscometer was 
positioned in a water bath at 30 ˚C.  Temperature changes were closely monitored using a glass 
thermometer as they could drastically alter the flow through times of the DNA solution.  The viscometer 
was anchored in the water bath so that the entire sample was submerged during testing.    
 Eight mL of tris-NaCl buffer was pipetted into the large arm of the viscometer and drawn up 
through the smaller arm using a 3-valve rubber pipette bulb.  The solution was drawn up until the bulb on 
the smaller arm of was completely filled.  Removing the bulb, gravity began drawing the meniscus of the 
solution down towards the white line directly above the bulb on the small arm of the viscometer.  Flow 
time of the solution was defined by the time it took the meniscus of the solution to move from the white 
line above the bulb to the white line directly below the bulb.  The trial was repeated 3 times and an 
average was calculated.  After the buffer runs were completed, the solution was disposed of and 8 mL of 
CT-DNA solution was pipetted into the viscometer and tested using the same procedure as used for the 
buffer.   
After the completion of three similar runs of the CT-DNA in buffer, the first addition of 
compound in DMSO and water was added to the viscometer and the existing CT-DNA solution.  The bis-
cation compound was prepared for addition by dissolving the pre-weighed amount first in 100 μL of 
DMSO and brought up to volume with 900 μL of DNase-RNase free water.  Eight microliter additions 
that would increase the concentration of compound in solution by 10 μM were chosen.  Using a pipette, 
the compound solution was deposited on the inner wall of the narrower arm approximately one inch from 
the top of the arm.  The three valve pipette bulb was used to draw the solution from the bulb on the wider 
arm up to where the compound was added to bring the compound into solution.  This was repeated 3-4 
times to ensure that the compound was completely removed from the wall and brought into solution.  
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Mixing of the solution occurred via a standard rubber pipette bulb which was used to force the solution 
from the thin arm through the loop and into the large bulb on the thicker arm.  The exerted pressure 
supplied to the bulb forced air through the viscometer and the solution in the bulb resulting in a bubbling 
effect.  The bubbling should be induced 2-3 times for a length of 1-2 seconds.  Once the solution is 
bubbled through, the three valve bulb can be used to draw up the solution for the first of the three trials.  
These steps were followed for the remaining 6 additions bringing the final concentration of the compound 
in solution to 70 μM after the final addition.       
FID Assay 
 The protocol utilized for the FID assay was adapted from Boger et al.8 and conducted on a Horiba 
Jobin Yvon Fluoromax-4 spectrofluorometer. The spectroflourometer was turned on and allowed to warm 
for 30 minutes prior to the beginning of the assay.  The intensity of the lamp alone and that of a cuvette 
filled with nanopure water were tested at the beginning of each day’s trial as controls to ensure that the 
instrument was working properly and the data collected would be representative of the compound tested.  
Using the CT-DNA stock solution, 2.997 mL of DNA and 3 μL ethidium bromide were pipetted into a 
clean, 4 mL cuvette.  The contents were mixed by pipette and the cuvette was placed in the sample holder 
of the spectrofluorometer.  The sample incubated for two minutes in the dark prior to measuring the 
emission spectrum of the sample from 465 nm to 765 nm with an excitation peak at 510 nm.  Following 
the run, data was extracted from the reading and inputted into an excel spreadsheet for ease of access.   
 The bis-cation compound was prepared for addition by dissolving the pre-weighed amount first in 
100 μL of DMSO and brought up to volume with 900 μL of DNase-RNase free water.  Additions 
consisted of 2 μL increments from 2-30 μL, 10 μL increments from 30-100 μL, and 100 μL increments 
from 100-600 μL.  During each addition, the given volume was pipetted directly into the cuvette, and 
mixed by pipette.  Once again, 2 minutes was given as an incubation period before analysis on the 
fluorometer.   
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Results and Discussion 
Weighing compounds for solutions  
 The compounds for each of the viscosity and FID trials were weighed out as seen in Table 1 
below. 
Table 1. The mass of each of the compounds needed to make a 1mL, 10 mM solution for viscosity assay 
and a 1mL, 5 mM solution for the FID assay. 
Mass of Compounds Needed for Solution 
Viscosity Assay FID Assay 
# of linker Mass (g)  # of linker Mass (g)  
2 0.0060 2 0.003 
4 0.0063 4 0.00315 
10 0.0072 10 0.0036 
12 0.0074 12 0.0037 
 
 
 
Viscosity Assay 
 Six separate trials were conducted for the viscosity assay; a vehicle control of 10% DMSO in 
water, the known DNA intercalator acradine orange, and the four compounds with ethyl, butyl, decyl, and 
dodecyl linkers.  After normalizing data to compensate for small variations in the temperature between 
trials, the trials were graphed as seen in Figure 2 below. 
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Figure 2. The normalized viscosity of each of the six trials graphed against the ratio of compound divided 
by the DNA concentration.   
 
The viscosity for the interactions of the DNA solution with both the dodecyl linker and the butyl linker 
showed activity that indicated more DNA intercalation that our reference solution, acradine orange.  
Although not as significant as the dodecyl and butyl linkers, the ethyl and decyl linkers showed moderate 
activity, but not to the extent of acridine orange.  As aforementioned, the bis-cation imadazolium salt 
series has varying solubility in water, and despite the addition of 10% DMSO, the compounds had issues 
with solubility that increased with linker length.  The ethyl and butyl compounds dissolved completely in 
solution for the duration of the trials, but the decyl and dodecyl compounds crashed out of solution 
several times between additions to the sample within the viscometer.  Despite the use of a Fisher 
Scientific Vortex to mix the contents, solid compound remained.  This insolubility likely resulted in 
inconsistent increases in concentration, suggesting the activity of the two compounds may be 
misrepresented by their data.  The concentration increases were likely reduced by the precipitated solids 
implying that the activity of these compounds may have been more significant than Figure 2 indicates. 
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 Solubility issues with our compounds present a large issue should there be a desire to move 
forward into cell tests based on the results of this study.  DMSO served as an agent to increase compound 
solubility in this study, but cannot be used in vivo due several unfavorable interactions within cells 
including inducing apoptosis in the CNS of mice9  and damaging mitochondrial integrity in astrocytes.10  
The oligosaccharide cyclodextrin may provide the answer as it has shown promise in drug delivery 
applications using its hydrophilic exterior and lipophilic interior to carry drugs through the bloodstream to 
their eventual targets.10  The Youngs group has experimented with the use of cyclodextrin for drug 
delivery systems, but use of the sugar with the bis-cation series has yet to be investigated using this 
viscosity assay.  
FID Assay 
 The intensity values collected for the FID assays on the spectrofluorometer were normalized 
against the intensity value recorded for 0 microliters compound added for each given day of testing.8 Data 
normalization ensures that the data collected from the given compounds are representative of their 
interactions with DNA and ethidium bromide and not altered by the decreasing power of the 
spectrofluorometer’s lamp or other changes that could occur with the device between the trials.  Analysis 
of data was completed for each of the four compounds, a vehicle control of 10% DMSO in water, and 
Netropsin, a reference compound known to displace ethidium bromide and intercalate with DNA.8 Figure 
3 visualizes the drops in intensity for each of the 6 trials for 2 µL additions from 0-30 µL.  All four of the 
compounds showed equally insignificant drops in intensity that did not rival that of the known DNA 
intercalator and ethidium bromide displacer, netropsin.  This trend continued as the volumes increased to 
10 µL and eventually to100 µL additions suggesting that the compounds do not have significant enough 
intercalation with CT-DNA to displace ethidium bromide.   
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Figure 3. The FID assay data for the four compounds, 10% DMSO vehicle control, and netropsin.  
Intensity measured on the spectrofluorometer was normalized each day and graphed against the 
concentration of the compound added for each individual trial. 
 
 The FID assay did produce some interesting findings that revealed an interaction that occurs 
between the bis-cation imidazolium salts with longer linkers and our CT-DNA solution.  Both the dodecyl 
and decyl linked compounds were found to precipitate the CT-DNA when volumes of the compounds 
exceeded 100 μL.  Precipitation of the DNA in solution resulted in a color change from a translucent, red-
pink color provided from the diluted ethidium bromide to a foggy, orange color.  These qualitative 
changes were accompanied by significant quantitative changes as well as intensity values in the foggy 
solutions were recorded 2-3 factors lower than previously measured.  This finding is extremely 
problematic as the precipitation of DNA would prohibit the compounds from realistically being used in 
vivo unless they are able to interact with a different intracellular target.       
Conclusions 
 In this study, bis-cation imidazolium salts with varying length linkers were tested to see if their 
interaction with CT-DNA might reveal a mechanistic action that could be utilized to treat NSCLC.  Two 
assays that test DNA intercalation, a viscosity assay and a fluorescence intercalation displacement assay, 
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were completed with inconsistent results.  The viscosity assay tested compounds against both a vehicle 
control and the known DNA intercalator acridine orange.  Despite solubility issues with the longer linked 
compounds that could have resulted in the addition of smaller concentrations, data showed an increase in 
viscosity.  The data collected indicated that the butyl and dodecyl linkers added greater strain to the DNA 
and increased viscosity more than acridine orange and that the ethyl and decyl linkers showed moderate 
activity, but not as significant as acridine orange.  Problems with solubility could have led to significant 
error in the exact values recorded, however, general trends in run-through times indicate all of the 
compounds increased viscosity.  The inclusion of the vehicle control proves that the viscosity was not 
increasing solely because of the 10% DMSO solution being added, but was a product of the compounds 
themselves.  Despite the positive results of this assay, the results do not give us any information about the 
placement of interaction within the major or minor grooves of DNA helices. Future studies of DNA 
intercalation with bis-cation compounds could reveal how the increases in viscosity are occurring.  
 The FID assay results did not indicate the same promise that the viscosity study did for the 
compounds.  Salts with ethyl and butyl linkers showed little to no intercalation displacement of ethidium 
bromide and appeared insignificant in comparison to the positive control, netropsin.  The dodecyl and 
decyl linkers showed similar inactivity at the lower concentrations before precipitating out the DNA once 
compound volume neared 100 μL.  DNA precipitation is a seriously problematic byproduct for 
compounds designed to be anti-tumor agents, so it is unlikely that compounds above a certain number of 
carbons could be used for future studies unless their mechanism of action leads them to an alternative 
intracellular target.  It is possible that a compound with a linker between 5-9 carbons could have the 
increased intercalation displacement of netropsin without precipitating out like the decyl and dodecyl 
compounds.  With the inconsistencies of our bis-cation series in relation to DNA interaction, the next 
logical step for the Youngs group will be to investigate others mechanisms of action for our bis-cation 
series.   
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Safety Appendix 
 
 Laboratory safety training and instruction was provided by Marie Southerland, the graduate 
student overseeing this project.  Standard Personal Protection Equipment (PPE) was required for all 
aspects of both of the assays conducted and students were required to wear nitrile gloves and safety 
glasses at all times.  Specific care was required for several of the reagents used in the study, especially the 
known DNA intercalators ethidium bromide, acridine orange, and netropsin.  Special waste containers for 
liquid samples that contained ethidium bromide or netropsin as well as solid samples that contained these 
reagents at some point (such as tips) were kept in a fume hood in sealed glass containers.  To limit 
handling by an undergraduate student, Marie was responsible for the addition of ethidium bromide into 
the CT-DNA samples during the FID assay trials to avoid any unnecessary risk and prevent spills.  After 
the completion of these trials, safety protocols were followed that involved disposing the samples and 
several washes of the cuvette containing them in the aforementioned waste containers before disposing 
any washes down the sink.  The less potent DNA intercalator acridine orange was handled with similar 
care to ethidium bromide taking specific precaution when dealing with concentrated stock solutions.  Due 
to its reduced toxicity, samples containing the reagent were discarded in normal aqueous, non-
halogenated waste after experiments. 
 Dimethyl sulfoxide (DMSO) was used during the study to increase the solubility of our 
compounds in water.  Although DMSO is generally regarded as safe in small volumes, the effects of our 
bis-cation imidazolium salts on human cell lines are generally unknown given the experimental nature of 
this study.  For this reason, special containers similar to those for ethidium bromide waste were kept in a 
fume hood for all aqueous solutions containing imidazolium salts without any ethidium bromide.  These 
containers were stored to be collected by the UA Health and Safety Department who ultimately decide the 
final neutralization and disposal methods.   
 In addition to the specific disposal protocols followed for this study, general health and safety 
practices were followed.  No food or drinks were allowed in the laboratory during the conducting of 
experiments and proper clothing such as closed toed shoes and pants covering the legs were required.  If 
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students did come in contact with chemicals during the course of the study, eye-wash and chemical 
shower station locations were highlighted by Marie Southerland.  Spilling of chemicals of any kind, 
splashing of reagents into eyes, nose, or mouth of an individual or cuts resulting from broken glassware 
were to be reported to Marie or Dr. Youngs and depending on the severity of the situation, the UA Health 
and Safety Department.    
  
 
  
 
 
 
